Home > Publications database > An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report. > print

001     282689
005     20240229155045.0
024 7 _ |a 10.1016/j.pmedr.2023.102368
|2 doi
024 7 _ |a pmid:37680853
|2 pmid
024 7 _ |a pmc:PMC10480621
|2 pmc
024 7 _ |a altmetric:153035656
|2 altmetric
037 _ _ |a DKFZ-2023-01835
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Waheed, Dur-E-Nayab
|b 0
245 _ _ |a An update on one-dose HPV vaccine studies, immunobridging and humoral immune responses - A meeting report.
260 _ _ |a Amsterdam [u.a.]
|c 2023
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1694183859_27134
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The 12th HPV Prevention and Control meeting was held on June 2-3, 2022, in Antwerp, Belgium. This technical meeting focused on several topics. This report summarises the discussions and lessons learned on two topics: an update on one-dose HPV vaccination studies and humoral immune responses upon HPV vaccination. Long-term follow-up studies from Costa Rica (eleven years) and India (ten years) report stable levels of antibodies after a single HPV vaccination. High vaccine effectiveness against incident persistent HPV 16/18 infection was seen in India (95.4%, 85.0-99.9) ten years postvaccination and in Kenya (97.5%, 81.7-99.7) eighteen months postvaccination, an important observation in a setting with a higher HPV prevalence. The potential impact of HPV vaccination using a one-dose schedule in India was modelled and showed that implementation of one-dose schedule can contribute towards achieving WHO Cervical Cancer elimination goals. These data support the WHO SAGE recommendations for adopting a one-dose schedule for females aged 9-20 years. Immunobridging studies were discussed during the meeting. General agreement was reached that when thoughtfully applied, they can support and accelerate the expanded use of HPV vaccine with new vaccine schedules, age cohorts, or vaccine formulations. Internationally standardised measurements of HPV immune responses important for the progress of HPV vaccinology field. Humoral immune responses upon HPV vaccination plateau at 24 months regardless of number of doses, therefore, data should be analysed after at least 24 months of follow-up to bridge studies accurately.
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Clinical trials
|2 Other
650 _ 7 |a Human papilloma virus
|2 Other
650 _ 7 |a Humoral immune responses
|2 Other
650 _ 7 |a Immunobridging
|2 Other
650 _ 7 |a Meeting report
|2 Other
650 _ 7 |a One dose
|2 Other
650 _ 7 |a Schedule
|2 Other
650 _ 7 |a Vaccination
|2 Other
700 1 _ |a Burdier, F Ricardo
|b 1
700 1 _ |a Eklund, Carina
|b 2
700 1 _ |a Baussano, Iacopo
|b 3
700 1 _ |a Mariz, Filipe Colaço
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Téblick, Laura
|b 5
700 1 _ |a Mugo, Nelly
|b 6
700 1 _ |a Watson-Jones, Deborah
|b 7
700 1 _ |a Stanley, Margaret
|b 8
700 1 _ |a Baay, Marc
|b 9
700 1 _ |a Vorsters, Alex
|b 10
773 _ _ |a 10.1016/j.pmedr.2023.102368
|g Vol. 35, p. 102368 -
|0 PERI:(DE-600)2785569-7
|p 102368
|t Preventive Medicine Reports
|v 35
|y 2023
|x 2211-3355
909 C O |o oai:inrepo02.dkfz.de:282689
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2023
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PREV MED REP : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T14:49:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T14:49:21Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T14:49:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-26
920 1 _ |0 I:(DE-He78)F035-20160331
|k F035
|l F035 Tumorvirus-spez. Vakzinierungsstrategie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F035-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21